Investment Banking Services that Drive Transformative Transactions

Our experienced senior bankers provide expert M&A advisory services to health sciences firms and investors seeking superior outcomes.

200+

Deals Closed

20+

Transactions Per Year

100%

Health Sciences Transactions

M&A Advisory

We are part of the fabric of the industries we serve. As a global M&A investment banking advisory firm, our services are delivered by a team of experienced senior bankers who have spent their careers developing deep professional relationships and building in-depth knowledge of the companies, trends and insights relevant to our core areas of industry focus. 

M&A - Image

Proven Process

Crosstree executes against, “The Standard,” a system designed to set the bar for quality, consistency, and outcomes.

01

360° Storytelling

With a solid foundation of data and a deep understanding of your industry, we build a clear, elegant story of substance to explain your value to potential buyers. 

02

Marketing Strategy

We match your company’s distinguishing characteristics and unique value proposition with market trends and buyer/investor fit, using thoughtful, disciplined qualification and scoring rigor

03

Competitive Bidding

Our reputation as expert health sciences advisors with high quality deals increases potential buyer confidence and attention

04

Exceptional Outcomes

We consistently and predictably achieve spike valuations and exceptional financial results for our clients.

M&A - Process

Crosstree’s Client Outcomes Consistently Exceed Industry Benchmarks

Crosstree’s deep industry focus fosters efficient project execution. Our relationships with investors and strategic buyers are unmatched in the industry.

M&A - Higher Valuations

Achieve higher valuations

Our deals consistently achieve “spike valuations” through concise articulation of client value propositions, credible financial and technical support, and thoughtful alignment of industry trends.

M&A - Confident

Be confident in your success

Our culmination of industry expertise that leverages market data, trends, and a high-profile network, drives an outstanding closing rate of almost 90%.

M&A - Accelerate

Accelerate your closings

By combining technology, structured project management methodology, and a focused process approach, We close transactions faster — with less resourcing strain on clients — compared to traditional investment banks.

Client Testimonials

/ 3
Recent M&A Transactions
Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities

Anju Software Acquired by Valsoft Corporation to Grow eClinical and Commercialization Capabilities

Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network

Pinnacle Clinical Research Acquired The Cognitive and Research Center of New Jersey to Expand Clinical Trial Site Network

Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network

Pinnacle Clinical Research Acquires Kerwin Medical Center to Bolster Clinical Trial Site Network

BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering

BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering

Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe

Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe

Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US

Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US

Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions

Calyx has divested its 'Enterprise Technology' Division to Ennov, to Enhance Ennov’s portfolio of eClinical and eRegulatory Software Solutions

physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research

physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research

Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities

Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform

QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally

QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities

Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities

Access Medical Labs Allies with Grupo Diagnostico Aries to Expand Diagnostic Lab Capabilities into North America

Access Medical Labs Allies with Grupo Diagnostico Aries to Expand Diagnostic Lab Capabilities into North America

Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities

Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities

Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities

Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities

anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally

anteris Acquired by Kymanox, a Portfolio Company of Westview Capital Partners, to Expand Injectable Combination Product Development Capabilities Globally

RMC Pharmaceutical Solutions Acquired by Syner-G Biopharma Group, a Portfolio Company of Riverside Partners, to Expand Regulatory Compliance Solutions

RMC Pharmaceutical Solutions Acquired by Syner-G Biopharma Group, a Portfolio Company of Riverside Partners, to Expand Regulatory Compliance Solutions